Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

Tue, 07th Dec 2021 21:49

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Premier Miton Group PLC - London-based asset manager - Closes year to September 30 with assets under management of GBP13.9 billion, up 31% from GBP10.6 billion at same point year before. Records GBP830 million of net inflows, reversed from GBP619 million outflows year before, particularly aided by continued success from several of its single strategy funds. Chief Executive Mike O'Shea says: "I am pleased to deliver a strong set of results for the group. We have achieved net inflows of GBP830 million in 2021, with all four quarters seeing positive flows. In terms of investment performance, 83% of our funds are outperforming since manager tenure. From a financial point of view, we have a healthy level of cash on our balance sheet and our AuM is at an all-time high." Annual pretax profit almost doubles to GBP17.5 million from GBP9.6 million as revenue surges 27% to GBP84.5 million from GBP66.8 million. Increases total annual dividend to 10.0 pence from 7.0p.

----------

Mercia Asset Management PLC - Henley-in-Arden, England-based investment company - Assets under management ends first half at GBP948 million, up from GBP940 million six months earlier and up from GBP872 million at same point year before. Operating profit in six months to September 30 grows to GBP10.7 million from GBP8.0 million year before, as revenue improves to GBP10.1 million from GBP8.4 million and books GBP8.7 million gain in fair value movements from investments. Declares interim dividend of 0.3 pence, up from 0.1p year before. Chief Executive Mark Payton says: "I am pleased with this strong performance and the continued growth and value creation that we have delivered across our portfolio in the six-month period under review. I believe that against a backdrop of economic recovery, this positive momentum is set to continue, reinforcing our position as one of the most active UK investors in our chosen areas across venture, private equity and debt."

----------

Iomart Group PLC - Glasgow-based cloud computing company - Pretax profit in six months to September 30 broadly flat year on year at GBP6.0 million, but revenue slips to GBP51.9 million from GBP56.3 million. Administrative expenses drops to GBP24.4 million from GBP27.6 million. Declares interim dividend of 2.42 pence, down from 2.6p a year before. Chief Executive Reece Donovan says: "We are energised by our refreshed strategy, new brand and clear focus. The early customer wins from the new sales campaigns are excellent signs that the strategy is on track and starting to deliver tangible results. iomart's high level of recurring revenue remains a considerable strength, providing good visibility for the remainder of the year. Current trading is in line with the board's expectations for the full year."

----------

Falanx Group Ltd - Reading, England-based cyber security - Pretax loss in six months to August 30 narrows to GBP746,906 from GBP1.4 million a year before. Interim revenue improves to GBP2.8 million from GBP2.5 million. Chair Alex Hambro says: "Following the disposal of Assynt in October 2021, Falanx is now a 'pure play' Cyber Security services business which is well positioned and financed to address the growing market opportunity created by constantly increasing risks in the digital world. Customer demand has grown significantly compared with the pre-pandemic environment. Our new initiatives are gaining interest from both direct customers and from our larger partners, and we are beginning to achieve sales of these innovative services. Our core service offerings of penetration testing, and protective monitoring are doing well, have moved into profitability and provide us with a solid foundation for growth with their large customer bases."

----------

Jaywing PLC - Sheffield, England-based data-driven advertising and marketing agency - Pretax loss in six months to September 30 narrows to GBP44,000 from GBP251,000 loss year before. Revenue improves to GBP15.1 million from GBP11.3 million. Chief Executive Andrew Fryatt says: "We are pleased to report net revenue growth of 24% in the first half, returning to pre-pandemic levels, despite what continues to be a challenging market. Net revenue per head increased by 22% year on year to GBP40,000. The business also achieved a significant improvement in underlying profitability, which has been somewhat masked by the impact of Covid-related support and salary sacrifice during 2020. Excluding these, Ebitda improved from GBP41,000 to GBP986,000."

----------

Webis Holdings PLC - Isle of Man-based gaming firm - Improves to pretax profit of USD824,000 in year ended May 31 from USD284,000 loss year before, as revenue grows to USD55.7 million from USD43.4 million. Chair Denham Eke says: "This is a very significant turnaround from our previous losses in 2020 and 2019 and shows signs of promise for the future. I am pleased to report an excellent performance from our core USA based business WatchandWager.com over the financial year with a significant surge in profitability. The company has proved to be robust despite the impact of Covid-19 upon our key content and operations. Our online business performed well, and our racetrack operation at Cal Expo was also remarkably resilient in the face of difficult operational challenges."

----------

Solid State PLC - Redditch, England-based electronic components manufacturer - Pretax profit in six months to September 30 slips to GBP2.1 million from GBP2.4 million a year before. Interim revenue grows 19% year on year to GBP39.4 million from GBP33.1 million. Half-year dividend rises to 6.25 pence from 5.25p. Chair Nigel Rogers says: "Our half year results are particularly pleasing given the widely reported challenges in the global supply chain and more local pressures in staffing and the foreign exchange headwinds at a revenue level. The successful acquisition programme has added resilience and opened up opportunities to grow the business in targeted regions and industry sectors. We continue to see acquisitions as a pillar of our growth strategy." Confident in meeting annual expectations, as order book at record of GBP70.3 million at September 30.

----------

Kinovo PLC - London-based gas heating, electrical and building services - Improves to pretax profit of GBP1.0 million in six months to September 30 from GBP449,000 loss year before. Revenue improves to GBP23.8 million from GBP14.5 million and administrative expenses drops to GBP560,000 from GBP1.2 million. Reinstates dividend, paying 0.5 pence to shareholders. Chief Executive David Bullen says: "This has been the first six-month period since we rebranded and repositioned the group. We are in an excellent position to better meet the needs of our customers, we are embracing our ESG responsibilities and continue to focus on our three strategic pillars of Regulation, Regeneration and Renewables. Revenues have increased 64% year on year and are well diversified across our strategic pillars and service divisions. In addition, we have continued to reduce our net debt and we have reinstated our final dividend payment."

----------

Zytronic PLC - Newcastle-upon-Tyne-based touch sensors manufacturer - Improves to pretax profit in year to September 30 of GBP453,000 from GBP423,000 loss year before. Revenue slips to GBP11.7 million from GBP12.7 million but administration costs falls to GBP2.9 million from GBP3.3 million. Notes second half sales rose 44% versus first half in "encouraging" recovery. Looking ahead, Chair Tudor Davies says: "The first two months of the year have seen an improvement in order intake, and with the improved margins and levels of demand across most sectors, this provides the basis for good progress in the coming year."

----------

Carr's Group PLC - agriculture machinery distributor and engineering firm - Raises its dividend after upbeat annual results. For financial year that ended August 28, pretax profit jumps 10% to GBP12.1 million from GBP10.9 million last year on revenue rise of 5.5% to GBP417.3 million from GBP395.6 million. Carr's declares total dividend of 5.0p, up 5.3% from 4.75p. Chair Peter Page says: "The group has delivered an excellent result ahead of the board's original expectations, with increased profits across both Agriculture divisions and an enhanced order book for Engineering. In large part, this result stems from the unwavering commitment of all employees."

----------

SDI Group PLC - Cambridge-based medical technology firm - Pretax profit in six months to October 31 improves to GBP5.1 million from GBP2.4 million year before. Revenue surges to GBP24.7 million from GBP14.1 million. Chair Ken Ford says: "We are pleased to report yet another strong set of financial results. SDI Group continues to execute on its business model, investing in quality businesses that are able to grow while generating cash. We look forward to delivering a full year performance in line with market expectations."

----------

Seed Innovations Ltd - Guernsey-based wellness and life sciences firm - Sinks to net loss of GBP1.6 million in six months to September 30 versus GBP961,000 profit year before. Makes investment loss of GBP1.1 million in first half from GBP1.5 million gain year before. Chair Ian Burns says: "We have made two investments into new companies during the period under review, both of which align with our focus to invest in disruptive technologies, but with a focus on investing within the medical cannabis, health and wellness space. Alongside these new investments, we have continued to support our existing portfolio companies, and collectively expand and balance out the liquidity of our portfolio." Portfolio ends half with net asset value of GBP23.4 million from GBP24.9 million at end of March.

----------

Evgen Pharma PLC - Liverpool-based sulforaphane based medical drug developer - Pretax loss in six months to September 30 narrows to GBP1.5 million from GBP1.9 million year before. Does not generate revenue in first half versus GBP194,000 year before. Total operating expenses falls to GBP1.5 million from GBP2.0 million. Chief Executive Huw Jones says: "The last six months has yielded further positive preclinical data to support the potential of SFX-01 in a number of cancers and an Orphan Drug Designation in the US for malignant glioma. With the scale up and refinement of the SFX-01 production process and design of the Phase I and Phase II clinical trials running in parallel, we look forward to commencing further important clinical programmes in the first half of 2022."

----------

CareTech Holdings PLC - London-based social care services provider - Pretax profit in year to September 30 surges to GBP66.2 million from GBP37.8 million year before. Revenue grows 14% to GBP489.1 million from GBP430.0 million. Annual dividend rises to 14.1 pence from 12.75p. Chief Executive Farouq Sheikh says: "I am particularly pleased to report another strong set of results, which are slightly ahead of market expectations. This performance continues to validate our belief that we have a well-executed strategy, which meets a critical social care need and has demonstrated resilience in a challenging market environment. Our fundamentals are strong, and we remain committed to providing high quality care to those we look after."

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.